Starpharma Holdings Share Price - SPL, RNS News, Articles, Share Price Quotes, Charts, & Stock Market information(ASX:SPL, SPL.AX)

Starpharma Holdings
www.starpharma.com/

Description

Starpharma Holdings (ASX: SPL) is focused on the development of dendrimer nanotechnology for pharmaceutical, drug delivery and other applications. Products based on Starpharma’s dendrimer technology are already on the market as diagnostic elements and laboratory reagents through licence agreements.

News

All News ►

Recent Sector News

iSonea rights issues provides better than expected return of A$4.6m

iSonea has received strong shareholder support for its recent renounceable rights issue which received subscriptions and commitments of 107% to raise A$4.6 million.
iSonea accelerates commercialisation of asthma devices in U.S., in negotiations with partners

iSonea is currently in negotiations with major strategic partners to accelerate commercialisation and cash flows of its next generation asthma products in the U.S. A measure of confidence in the company’s plan is that $3.7 million of its $4.3 million rights issue will be underwritten.
Medical Australia boosts FY2012 revenue by A$1.5m with new supply agreements

New supply contracts indicate the strong organic revenue growth Medical Australia is experiencing across the business and with further prospects the company is on a solid growth footing for FY2012 and beyond.
Circadian Technologies moves into clinical development phase on approval of IND for cancer drug

The FDA’s approval of Circadian’s Investigational New Drug application for its antibody to treat cancer means the company is now well placed to begin the transition to a clinical development company.
Circadian Technologies: Van Leeuwenhoeck places share price target of $1.97

Van Leeuwenhoeck considers Circadian as "gravely undervalued at current share price of $0.50", and based on a sum-of-the-parts valuation, values the company at A$1.97 - around four times the last traded price - highlighting significant upside potential.
Circadian Technologies looks to royalties on cancer diagnostic test with Healthscope

Healthscope has paid Circadian an upfront fee, and will pay a royalty on sales of the CUP test. The CUP test will be commercially available early next year, ringing in the transition for Circadian into a clinical development company.